Gilead Sciences (NASDAQ: GILD) shares fell 2.3% to $101.25 after the company reported that it has signed licensing agreements with seven India-based generic pharmaceutical manufacturers to expand access to its hepatitis C treatments in developing countries. Share volume totaled 13.6 million, compared to an all-day average of 12.9 million
